The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year ...

NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

A new study developed a mineralized DNA hydrogel that combines immune regulation with sustained bone regeneration. Using ...

Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...

In a recent study posted to the bioRxiv* preprint server, researchers performed age-reversing experiments, in vivo and in vitro, in progeroid mice using gene therapy. Study: Gene Therapy Mediated ...

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary ...

For those hoping to cure death, and they are legion, a 2016 experiment at the Salk Institute for Biological Studies in San Diego has become liminal — the moment that changed everything. The experiment ...

Researchers have attained the holy grail of cellular reprogramming: inducing pluripotency without using any DNA-based materials. Using only a cocktail of purified proteins and a chemical additive, ...

The result is a widely anticipated landmark for rejuvenation technology. A small biotech company claims it has used a technology called reprogramming to rejuvenate old mice and extend their lives, a ...

Mesenchymal drift may help explain how cells lose stable identity and acquire pro-fibrotic, inflammatory mesenchymal traits ...